Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma

0 Comments 5 view(s)

Positive news flowed in at Teva Pharmaceutical Industries Ltd. TEVA when the European Commission approved its marketing authorisation application for Cinqaero (reslizumab; interleukin-5 (IL-5) antagonist monoclonal antibody) for use as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

The EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion this June.

The company expects to make Cinqaero commercially available in Europe within a few upcoming months. We remind investors that Cinqaero is already marketed in the U.S. and Canada under the trade name Cinqair. Regulatory applications in other global markets are, however, pending.

TEVA PHARM ADR Price

 

 

TEVA PHARM ADR Price | TEVA PHARM ADR Quote

We note that GlaxoSmithKline plc’s GSK Nucala, another IL-5 antagonist monoclonal antibody, is marketed in both the U.S. and the EU. Meanwhile, companies like AstraZeneca plc AZN are also looking to bring their anti-IL-5 antibodies to the market for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD).

Meanwhile, Teva has several programs ranging from phase I to registration in its pipeline with many of these focused on the central nervous system and the respiratory system (asthma, COPD and allergic rhinitis). As far as other therapeutic areas like women’s health and oncology are concerned, Teva is focusing on market-ready or close-to-market products to maximize sustainable profitability.

Teva is a Zacks Rank #3 (Hold) stock. Anika Therapeutics Inc. ANIK is a better-ranked stock in the healthcare sector, sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
 
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
 
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
 
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Powered by WPeMatico